Evidence map›Paper›PMID 40716510›Full record

ReviewDrug discovery today2025

Transcription factor YBX1 orchestrates drug resistance and tumor progression in HCC.

Dennis Kwabiah, Veerababu Nagati, Manish K Tripathi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drug discovery today, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Dennis KwabiahSchool of Integrative Biological and Chemical Sciences, University of Texas Rio Grande Valley, Edinburg, TX 78539, USA; Medicine and Oncology ISU, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA; South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
Veerababu NagatiMedicine and Oncology ISU, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA; South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
Manish K TripathiMedicine and Oncology ISU, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA; South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA. Electronic address: manish.tripathi@utrgv.edu.

Funding

Role of lncRNA UCA1 in anoikis resistantce and colorectal cancer metastasisR16GM146696 · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · 2025 to 2025
$185k
NIGMS NIH HHS R16 GM146696
6 · The paper itself

Abstract

Drug resistance continues to be a significant challenge in cancer treatment, responsible for over 90% of worldwide cancer-related deaths. Transcription factors (TFs), which control vital cellular processes, also play a crucial role in cancer development and resistance. In hepatocellular carcinoma (HCC), resistance to sorafenib, a primary targeted therapy, significantly impairs treatment effectiveness and worsens patient outcomes. Among TFs, Y-box binding protein 1 (YBX1) has been recognized as a regulator of aggressive cancer traits in colorectal and breast cancers. However, its role in HCC and sorafenib resistance remains unclear. This review examines YBX1's role in HCC progression and drug resistance, its underlying molecular mechanisms, and its potential as a biomarker and therapeutic target for overcoming sorafenib resistance.

Indexed as

Carcinoma, HepatocellularDrug Resistance, NeoplasmLiver NeoplasmsY-Box-Binding Protein 1AnimalsAntineoplastic AgentsDisease ProgressionHumansSorafenibAntineoplastic AgentsSorafenibY-Box-Binding Protein 1YBX1 protein, humandrug resistancehepatocellular carcinomakinasesorafenibY-box binding protein 1 (YBX1)

Identifiers

PMID40716510
PMCPMC12815576

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.